Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by mstrmndon Jun 11, 2020 10:21am
166 Views
Post# 31138299

RE:RE:Low's are over

RE:RE:Low's are overBayer should have bought yesterday.  I made a couple calls last night to suggest taking ATE.V private as a pure hostage play.  These billionaires have too much time on their hands.  The excitement and gratification of investing in something that will help others is worth WAY more than the money.  They will obviously easily profit 10-20x on the re-entrance to a public market.  

If this SP doesn't move up, the only losers will be the current shareholders when we get shares of another public company on a different exchange a multiple of the day of the halt.  It SO obvious what's happening here.  

Drive the SP up otherwise it would be 4 x $0.465 instead of 4 x $1.80 then the annoucement comes in and ATE.V is off the TSX.V.  Why keep the price low???  Because the other party (partner or M & A) is going to profit from ATE.V because of the s*hitty Afghanada Toronto Ventures Exchange


rick1988 wrote:
Hello all,
I would hope that everyone can see the accumalation taking place here, it is beyond apparent that Market Makers are in full control and for all  the right reasons.. Phase 2 data package is complete and we have the best outcome possible "A drug so potent and safe that the lowest does is yet to be established!!!!!" we are now a Phase 3 company and a serious threat to a company's profits  that has had considerable misteps over the past few years and watched its market cap shrink expotentially! cough hak cough uhhhh Bayer.... I agree with Mstrmnd this road may be alittle bit bumpy and windy but its not if.... Its when and if you are big pharma you cannot afford to look the other way on this one..


<< Previous
Bullboard Posts
Next >>